Dosing and uses of Pandel (hydrocortisone probutate topical)
Adult dosage forms and strengths
topical cream
- 0.1%
Corticosteroid-Responsive Dermatoses
Medium potency corticosteroid indicated for relief of inflammatory and pruritic manifestations of dermatoses
Apply sparingly to affected area qDay or BID depending on severity of condition
Administration
Apply a thin film to the affected area and massage gently until the cream disappears
Occlusive dressings may be used for the management of refractory lesions of psoriasis and other deep-seated dermatoses, such as localized neurodermatitis (lichen simplex chronicus)
Should not be used with occlusive dressings unless directed by the physician
As with other corticosteroids, therapy should be discontinued when control is achieved
If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary
Pediatric dosage forms and strengths
<18 years: Safety and efficacy not established
Pandel (hydrocortisone probutate topical) adverse (side) effects
1-10%
Burning (2%)
Stinging (1%)
<1%
Paresthesia
Frequency not defined
Itching
Irritation
Dryness
Folliculitis
Hypertrichosis
Acneiform eruptions
Hypopigmentation
Perioral dermatitis
Allergic contact dermatitis
Secondary infections
Skin atrophy
Striae
Miliaria
Warnings
Contraindications
Hypersensitivity
Cautions
Systemic absorption of topical corticosteroids may suppress the HPA axis
Application to large surface areas or areas under occlusion may increase risk for HPA axis suppression
Children are more susceptible to systemic toxicity because of their larger skin surface to body mass ratios
Discontinue if irritation develops
If concomitant skin infection is present or develops, use appropriate antibacterial or antifungal agent; discontinuation of topical corticosteroid may be required if infection inadequately controlled
Avoid contact with eyes
Pregnancy and lactation
Pregnancy category: C
Lactation: Systemic corticosteroids distributed in breast milk; unknown whether topical corticosteroids results in is sufficient systemic absorption to be detectable in breast milk distributed in breast milk
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Pandel (hydrocortisone probutate topical)
Mechanism of action
Medium potency corticosteroid Elicits anti-inflammatory, anti-pruritic, and vasoconstrictive actions; acts by the induction of phospholipase A2 inhibitory proteins (lipocortins); these proteins control the biosynthesis of potent mediators of inflammation (eg, prostaglandins, leukotrienes) by inhibiting the release of their common precursor arachidonic acid
Absorption
Extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle, integrity of the epidermal barrier, extent surface area
Occlusive dressings
